|Bid||0.2211 x 700|
|Ask||0.2284 x 300|
|Day's Range||0.2100 - 0.2320|
|52 Week Range||0.2100 - 4.3500|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
A bankruptcy judge approved $35 million in new loans for drugmaker Orexigen Therapeutics, which said it would use some of the money to advertise its anti-obesity drug, Contrave.
Drugmaker Orexigen filed for bankruptcy protection on Monday and plans to sell itself, after failing to find a profitable market for its weight-loss treatment Contrave.
Biopharmaceutical company Orexigen Therapeutics plans to sell itself later this year through bankruptcy proceedings.
Drugmaker Orexigen Therapeutics Inc said on Monday it filed for Chapter 11 bankruptcy protection and will also file a motion to pursue an auction and sale process of substantially all its assets. The company, which focuses on the treatment of obesity, said it expects proposed bids to be submitted by May 21 and the sale is intended to be concluded by July 2. Orexigen listed assets in the range of $50 million to $100 million and liabilities in the range of $100 million to $500 million, according to a filing in the Delaware bankruptcy court.
SAN DIEGO, March 12, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. Orexigen also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers to acquire substantially all of Orexigen's assets, which would be purchased free and clear of the company's indebtedness and other liens and interests.
In this article, I’m going to take a look at Orexigen Therapeutics Inc’s (NASDAQ:OREX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Orexigen Therapeutics, Inc. Here are 5 ETFs with the largest exposure to OREX-US. Comparing the performance and risk of Orexigen Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Orexigen Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Orexigen Therapeutics, Inc. – Arena Pharmaceuticals, Inc., VIVUS, Inc., Zafgen, Inc. and Lannett Company, Inc. (ARNA-US, VVUS-US, ZFGN-US and LCI-US) that have also reported for this period. Highlights ... Read more (Read more...)
Investors in Orexigen Therapeutics (OREX) need to pay close attention to the stock based on moves in the options market lately.
Orexigen Therapeutics Inc (NASDAQ:OREX), a USD$27.89M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
Orexigen Therapeutics Inc (NASDAQ:OREX), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs ofRead More...
On a per-share basis, the La Jolla, California-based company said it had a loss of $1.35. The drug developer for obesity and weight loss posted revenue of $18.9 million in the period. In the final minutes ...
Orexigen reports Contrave total third quarter prescription volume in the United States grew 26% year-over-year SAN DIEGO , Nov. 13, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today ...
SAN DIEGO , Nov. 13, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Merck KGaA, Darmstadt, Germany ...
SAN DIEGO , Oct. 31, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the third quarter of 2017 on Monday, November 13 th after the market ...
NEW YORK, NY / ACCESSWIRE / October 16, 2017 / U.S. markets rose Friday to close the week in the green as investors appear to be expecting a strong earnings season. The Dow Jones Industrial Average gained ...
SAN DIEGO, Oct. 13, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX) announced today that the United States District Court for the District of Delaware issued a ruling in favor of Orexigen in the paragraph IV litigation against Actavis Laboratories FL, Inc. (Actavis) for three patents for Contrave® (naltrexone HCl / bupropion HCl extended release) with exclusivity through 2030. "Orexigen's intent was to vigorously defend our intellectual property and we are very pleased with the Court's decision upholding the validity of all of the patents involved in the case," said Michael Narachi, President and CEO of Orexigen.
SAN DIEGO , Oct. 12, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that management will present at the 2017 BIO Investor Forum on Tuesday, October 17 th , at 9:15 AM PDT ...
For Orexigen Therapeutics Inc’s (NASDAQ:OREX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...